Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Options
BORIS DOI
Publisher DOI
PubMed ID
29055209
Description
BACKGROUND
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available.
METHODS
We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy.
FINDINGS
With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years.
INTERPRETATION
Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available.
METHODS
We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy.
FINDINGS
With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years.
INTERPRETATION
Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.
Date of Publication
2017-11
Publication Type
Article
Subject(s)
Keyword(s)
Acute myeloid leukemia FLT3-ITD Hematopoietic stem cell transplantation Sorafenib
Language(s)
en
Contributor(s)
Metzelder, S K | |
Schroeder, T | |
Lübbert, M | |
Ditschkowski, M | |
Götze, K | |
Scholl, S | |
Meyer, R G | |
Dreger, P | |
Basara, N | |
Salih, H R | |
Finck, A | |
Giagounidis, A | |
Kobbe, G | |
Wollmer, E | |
Finke, J | |
Neubauer, A | |
Burchert, A |
Additional Credits
Series
European journal of cancer
Publisher
Elsevier
ISSN
0959-8049
Access(Rights)
restricted